Beyond Air, Inc. Share Price
NASDAQ: XAIR | Small CapBeyond Air, Inc. Stock Performance
Open $4.34 | Prev. Close $5.38 | Circuit Range N/A |
Day Range $4.34 - $4.61 | Year Range $0.34 - $7.68 | Volume 3,172 |
Average Traded $4.53 |
Beyond Air, Inc. Share Price Today
As of 29 August 2026, Beyond Air, Inc.'s share price is $4.45. The stock opened at $4.34, compared to its previous close of $5.38. During today's trading session, Beyond Air, Inc.'s share price traded between $4.34 and $4.61, with an average price of $4.47. Over the past 52 weeks, the stock has recorded a high of $7.68 and a low of $0.34. In terms of performance, Beyond Air, Inc.'s share price has risen by 363.54% over the last six months and is up 100.90% on a year-on-year basis.
Beyond Air, Inc. Share Price Chart
Beyond Air, Inc. Stock Fundamentals & Key Indicators
Market Cap $301.29M | PE Ratio (TTM) -6.45 | Dividend Yield N/A |
EPS (TTM) $-0.69 | Revenue (TTM) $3.71M | Return On Equity (TTM) -356.91% |
Profit Margin -1308.48% | Debt to Equity 0.37 | Quarterly Earnings Growth YoY 43.71% |
Beyond Air, Inc. Quarterly Profit & Loss
All figures in USD
Beyond Air, Inc. Annual Profit & Loss
All figures in USD
About Beyond Air, Inc.
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Beyond Air, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $6.57 | $5.38 | -2.18% |
Jul 2026 | $0.45 | $5.50 | +1,138.74% |
Jun 2026 | $0.47 | $0.44 | -6.13% |
May 2026 | $0.51 | $0.47 | -1.25% |
Apr 2026 | $0.73 | $0.48 | -34.11% |
Mar 2026 | $0.91 | $0.73 | -24.27% |
Feb 2026 | $1.16 | $0.96 | -20.00% |
Jan 2026 | $0.74 | $1.20 | +63.49% |
Dec 2025 | $1.33 | $0.73 | -43.97% |
Nov 2025 | $1.91 | $1.31 | -36.41% |
Oct 2025 | $2.41 | $2.06 | -11.97% |
Sep 2025 | $2.30 | $2.34 | +5.64% |
XAIR Share Price FAQs
What is Beyond Air, Inc. share price today?
What is the 52 week high and 52 week low of Beyond Air, Inc. stock?
What is XAIR's market capitalisation today?
What is XAIR's net income for the last quarter?
What is the 5 year returns of XAIR?
What is the high & low stock price of XAIR today?
Can I buy XAIR shares in India?